|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:Jakafi
|
|
gptkbp:activities
|
Janus kinase inhibitor
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:availability
|
prescription only
|
|
gptkbp:brand
|
gptkb:Xeljanz
|
|
gptkbp:class
|
gptkb:Cloud_Computing_Service
|
|
gptkbp:clinical_trial
|
Phase II
Phase III
approximately 80%
Phase I
|
|
gptkbp:contraindication
|
active infections
severe liver impairment
|
|
gptkbp:developed_by
|
gptkb:Pfizer
|
|
gptkbp:dosage_form
|
5 mg tablet
10 mg tablet
|
|
gptkbp:effective_date
|
gptkb:2012
|
|
gptkbp:formulation
|
gptkb:tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Tofacitinib
|
|
gptkbp:ingredients
|
C16 H20 N6 O
|
|
gptkbp:interacts_with
|
live vaccines
other immunosuppressants
CY P450 inducers
CY P450 inhibitors
|
|
gptkbp:invention
|
2028
patented
|
|
gptkbp:is_monitored_by
|
liver function tests
complete blood count
lipid levels
infection signs
|
|
gptkbp:is_used_for
|
gptkb:ulcerative_colitis
gptkb:rheumatoid_arthritis
gptkb:psoriatic_arthritis
|
|
gptkbp:manager
|
oral
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:Xeljanz_XR
gptkb:Australia
gptkb:United_States
gptkb:Native_American_tribe
Xeljanz Oral Solution
|
|
gptkbp:research_areas
|
autoimmune diseases
rheumatology
inflammatory diseases
gastroenterology
|
|
gptkbp:safety_features
|
Lactation risk not established
Pregnancy Category C
|
|
gptkbp:side_effect
|
gptkb:healthcare_organization
headache
nausea
diarrhea
cardiovascular events
thrombosis
increased risk of infections
pulmonary embolism
elevated liver enzymes
|
|
gptkbp:weight
|
312.37 g/mol
|
|
gptkbp:year_created
|
gptkb:2009
|